Literature DB >> 16985675

Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma.

Ganesh S Palapattu, Blaine Kristo, Jacob Rajfer.   

Abstract

Renal cell carcinoma is unique among the genitourinary malignancies in that close to one third of affected patients show signs and symptoms of a paraneoplastic syndrome. The paraneoplastic syndromes associated with renal cell carcinoma range from those manifesting in constitutional symptoms (ie, fever, cachexia, and weight loss) to those that result in specific metabolic and biochemical abnormalities (ie, hypercalcemia, nonmetastatic hepatic dysfunction, amyloidosis, etc). The presence of a paraneoplastic syndrome in a patient with renal cell carcinoma is neither a marker of metastatic disease nor necessarily indicative of a poor prognosis. The importance of understanding the pathophysiology and biology behind the many paraneoplastic syndromes associated with renal cell carcinoma lies in the fact that the presence of these protean symptoms may be the initial presentation of either primary or recurrent disease. In this review, we will describe the proposed mechanisms of action of the many paraneoplastic syndromes associated with renal cell carcinoma as well as outline the clinical evaluation and treatment options currently available for these noteworthy disorders.

Entities:  

Year:  2002        PMID: 16985675      PMCID: PMC1475999     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  49 in total

1.  THE HEPATOPATHY OF HYPERNEPHROMA.

Authors:  W T LEMMON; P V HOLLAND; J M HOLLAND
Journal:  Am J Surg       Date:  1965-09       Impact factor: 2.565

2.  Hypercalcemia in malignant disease without evidence of bone destruction.

Authors:  A GELLHORN; C H PLIMPTON
Journal:  Am J Med       Date:  1956-11       Impact factor: 4.965

3.  Human chorionic gonadotropin expression in lung, breast, and renal carcinomas.

Authors:  C A Kuida; G D Braunstein; P Shintaku; J W Said
Journal:  Arch Pathol Lab Med       Date:  1988-03       Impact factor: 5.534

4.  Erythropoietin coming of age.

Authors:  A Erslev
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

5.  Ectopic production of human chorionic gonadotrophin by neoplasms.

Authors:  G D Braunstein; J L Vaitukaitis; P P Carbone; G T Ross
Journal:  Ann Intern Med       Date:  1973-01       Impact factor: 25.391

6.  Erythropoietin levels in patients with renal tumors or cysts.

Authors:  G P Murphy; G M Kenny; E A Mirand
Journal:  Cancer       Date:  1970-07       Impact factor: 6.860

7.  Bilateral diaphragmatic paralysis as a possible paraneoplastic syndrome from renal cell carcinoma.

Authors:  N E Thomas; P M Passamonte; E V Sunderrajan; J B Andelin; L E Ansbacher
Journal:  Am Rev Respir Dis       Date:  1984-03

8.  Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production.

Authors:  S Fukumoto; T Matsumoto; H Yamoto; H Kawashima; Y Ueyama; N Tamaoki; E Ogata
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

9.  The relationship of lactoferrin to the anemia of renal cell carcinoma.

Authors:  K R Loughlin; R F Gittes; D Partridge; P Stelos
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

10.  A renin-secreting tumor.

Authors:  R Pedrinelli; L Graziadei; S Taddei; M Lenzi; A Magagna; G Bevilacqua; A Salvetti
Journal:  Nephron       Date:  1987       Impact factor: 2.847

View more
  56 in total

Review 1.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

Review 2.  Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?

Authors:  Michael Garcia-Roig; Nicolas Ortiz; Vinata Lokeshwar
Journal:  Curr Urol Rep       Date:  2014-01       Impact factor: 3.092

3.  Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.

Authors:  Daniel M Moreira; Boris Gershman; Christine M Lohse; Stephen A Boorjian; John C Cheville; Bradley C Leibovich; Robert Houston Thompson
Journal:  World J Urol       Date:  2016-02-25       Impact factor: 4.226

4.  Limited scleroderma with pauci-immune glomerulonephritis in the presence of renal cell carcinoma.

Authors:  Victor Abrich; Sudhir Duvuru; Howard J Swanson
Journal:  Clin Med Res       Date:  2013-05-08

5.  Paraneoplastic Puzzle: An Unusual Case of Hemichorea, Renal Cell Carcinoma, and LGI1 Antibody.

Authors:  Kalea Colletta; Ninith Kartha; Jasvinder Chawla
Journal:  Mov Disord Clin Pract       Date:  2018-05-07

6.  Renal cell carcinoma with sarcomatoid transformation, presenting as skin rashes.

Authors:  Nitin Shrivastava; Brusabhanu Nayak; Prabhjot Singh
Journal:  BMJ Case Rep       Date:  2018-05-30

Review 7.  Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma.

Authors:  M Hegemann; N Kroeger; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2018-02-10       Impact factor: 4.226

Review 8.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

Review 9.  Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.

Authors:  Halit Karaca; Ayhan Lale; Mustafa Dikilitas; Metin Ozkan; Ozlem Er
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

10.  Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Authors:  David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2018-01-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.